QuantaFlo vs ABI Testing – Which is the Best?
QuantaFlo vs ABI: Here are some of the leading reasons that top medical providers choose QuantaFlo ™ testing for assisting in the diagnosis of Peripheral Arterial Disease (PAD) rather than settling for conventional :
QuantaFlo vs ABI: QuantaFlo is More Efficient than ABI
With the QuantaFlo System from Semler Scientific, accurate PAD testing and results reporting can be done in minutes by medical aides on the frontlines of medical care where it counts most: in the primary care office, in specialty medical practices, during home health visits, and at health fairs. In contrast, accurate ABI test results require specially-trained vascular technicians with years of experience working in dedicated vascular laboratories and only after a physician has prescribed the testing. This is like only being prescribed a blood pressure test if your physician suspects you have high blood pressure.
QuantaFlo is FDA-cleared for the Diagnosis of PAD
The FDA has cleared the QuantaFlo System to aid in the diagnosis of Peripheral Arterial Disease through the QuantaFlo 510(K). In addition, the system is in keeping with the 2016 AHA/ACC Guidelines on the Management of Patients with Lower Extremity Peripheral Arterial Disease.
QuantaFlo is Created and Backed by Proven Medical Experts
The core QuantaFlo technology was developed by well-known cardiologist Herbert Semler, MD who has over 50 years in medical practice, vast experience with older ABI technologies, and a history of cardiovascular innovation and inventions to help patients. In addition, Semler Scientific’s physicians, nurses and other employees have literally decades of medical experience and a proven track record of success in bringing ground-breaking medical technologies to the market.
QuantaFlo vs ABI: QuantaFlo is More Practical than ABI
When it comes to diagnosing PAD, relying solely on the physician’s physical exam and patient reports of symptoms has proven to be insufficient. Many patients with peripheral artery disease or PAD are asymptomatic and unless the physician suspects PAD, they would not normally be referred for an ABI test. By routinely testing patients at high risk for PAD in the primary care office with QuantaFlo, many patients benefit from early warning and the opportunity to make lifestyle changes such as increased exercise, better diet and smoking cessation which may help avoid future vascular interventions. Patients at high risk can include those over 65 not previously diagnosed with PAD, patients over 50 years old with a history of smoking or diabetes, or patients with claudication, critical limb ischemia (CLI), non-healing ulcer/wound or neuropathic leg pain.
QuantaFlo System Has Successfully Tested Hundreds of Thousands of Patients
The QuantaFlo System has been proven effective in daily use throughout the country in medical offices, hospitals, clinics and during home health visits. Keep in mind, PAD is one of the leading causes of strokes among many health issues.
You might also be interested in these related articles: